FDA Approves ORZEYFUL for Narcolepsy Type 1, Offering New Treatment Options
The U.S. Food and Drug Administration (FDA) has approved ORZEYFUL, an oral orexin receptor 2 agonist, for treating narcolepsy type 1 (NT1) in adults. Developed by Takeda, ORZEYFUL is the first medication in the U.S. to address the full spectrum of NT1 symptoms, including excessive daytime sleepiness and cataplexy. Clinical trials demonstrated significant improvements in patients compared to those on a placebo. The approval marks a significant advancement in NT1 treatment, providing a holistic approach rather than targeting individual symptoms.